# US 2024/0003899 A1 · Method for detection of analytes in a single tissue sample from ito slides using msi-lcm

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003899 A1
- Document ID: US20240003899A1
- Status: Published application
- Kind: A1
- Application number: 18/036,930
- Filed: 2021-10-13
- Published: 2024-01-04
- Earliest claimed: 2020-10-13
- Applicants: Universiteit Maastricht; Academisch Ziekenhuis Maastricht
- Inventors: Berta CILLERO PASTOR; Ronald Martinus Alexander HEEREN; Stephanie Theresia Petronella MEZGER
- Web page: https://patentgrep.com/patent/US20240003899A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/6851: {Methods of protein analysis involving laser desorption ionisation mass spectrometry}
- G01N 1/2806: {Means for preparing replicas of specimens, e.g. for microscopal analysis}
- G01N 1/286: {involving mechanical work, e.g. chopping, disintegrating, compacting, homogenising (microtomes G01N1/06; pulverising in general B02C; mixing in general B01F)}
- G01N 2001/2886: {Laser cutting, e.g. tissue catapult}
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a method for the detection of analytes in a tissue sample, wherein a combination of mass spectrometry imaging (MSI) analysis and laser capture microdissection (LCM) is carried out on a tissue sample on a conductive glass slide, using the same section for MSI and LCM. The method can be used for the detection of proteins, lipids, metabolites and glycans.

## Claims

### Claim 1

A method for the detection of analytes in a tissue sample, comprising the steps of:
applying the tissue sample to a glass slide having an electrically conductive coating;
carrying out a mass spectrometry imaging (MSI) analysis of the tissue sample on the glass slide;
subjecting the tissue sample to laser capture microdissection (LCM) to dissect sample material from the tissue sample on the same glass slide; and
analysing the dissected sample material to detect the analytes,
wherein the laser capture microdissection is carried out in ablation mode.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the analytes are proteins, lipids, glycans or metabolites.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the analytes are proteins.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the proteins originate from cellular and sub-cellular components, preferably selected from mitochondria, cytoplasm, nuclei and cytoskeleton or they can be extracellular matrix proteins.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the glass slide is coated with an indium tin oxide coating.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the mass spectrometry imaging analysis is selected from MALDI (Matrix-Assisted Laser Desorption-Ionization) and SIMS (Secondary Ion Mass Spectrometry).

### Claim 7 (depends on 6)

The method according to claim 6, wherein the MSI analysis is MALDI MSI, and wherein the method further comprises a step of applying a matrix onto the tissue sample before carrying out the MALDI-MSI analysis and a step of removing the matrix after carrying out the MALDI-MSI analysis.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the matrix is selected from α-cyano-4-hydroxycinnamic acid (CHCA), sinapic acid (4-hydroxy-3,5-dimethoxycinnamic acid), 2,5-dihydroxybenzoic acid (DHB), 2-(4-hydroxy phenyl azo) benzoic acid (HABA), succinic acid, 2,6-dihydroxy acetophenone, ferulic acid, caffeic acid (3,4-dihydroxy-cinnamic acid), 2,4,6-trihydroxy acetophenone, 3-hydroxypicolinic acid, 2-aminobenzoic acid, nicotinic acid, trans-3-indoleacrylic acid, isovanillin, dithranol, 9-aminoacridine (9-AA) and β-carboline (Norharmane).

### Claim 9 (depends on 1)

The method according to claim 1, wherein the MSI analysis is used to define a region of interest (ROI).

### Claim 10 (depends on 9)

The method of claim 9, wherein the ROI is ablated in the LCM step.

### Claim 11 (depends on 1)

The method of claim 1, wherein the ablated tissue sample is collected.

### Claim 12 (depends on 11)

The method of claim 11 wherein the collected tissue sample is treated for storage or further analysis.
